Stock VANTABIO6 VANTA BIOSCIENCE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vanta Bioscience Limited

Equities

VANTABIO6

INE695X01011

Biotechnology & Medical Research

Delayed Bombay S.E.
Other stock markets
 02:12:20 2024-04-29 am EDT 		5-day change 1st Jan Change
66.15 INR +5.00% Intraday chart for Vanta Bioscience Limited +9.72% +23.53%
Apr. 03 Vanta Bioscience Bags INR12 Million Order to Conduct Technical Studies MT
Apr. 02 Vanta Bioscience Limited Receives an Order of INR 12 Million from A Large Indian Multinational Company CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 212.9 1,176 574.4 1,029 693.4 362.9
Enterprise Value (EV) 1 278.8 1,256 746.1 1,362 1,140 933.6
P/E ratio 1,060 x 139 x 57.2 x 229 x 786 x -5.6 x
Yield - - - - - -
Capitalization / Revenue 5.34 x 9.46 x 4.06 x 10.2 x 6.92 x 5.26 x
EV / Revenue 7 x 10.1 x 5.28 x 13.6 x 11.4 x 13.5 x
EV / EBITDA 27 x 38.1 x 17.1 x 34.1 x 30 x -52.6 x
EV / FCF - -16,438,443 x -8,148,129 x -7,741,398 x -8,722,259 x -2,923,910 x
FCF Yield - -0% -0% -0% -0% -0%
Price to Book 1.74 x 4.34 x 2.45 x 4.3 x 2.77 x 2.07 x
Nbr of stocks (in thousands) 4,216 7,686 6,312 6,312 6,312 6,312
Reference price 2 50.50 153.0 91.00 163.0 109.8 57.50
Announcement Date 7/20/18 9/5/19 9/5/20 12/7/21 9/6/23 9/6/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 39.86 124.2 141.4 100.4 100.2 68.95
EBITDA 1 10.31 32.97 43.69 39.99 37.99 -17.75
EBIT 1 4.592 25.86 31.8 27.48 24.83 -44.45
Operating Margin 11.52% 20.81% 22.49% 27.37% 24.78% -64.47%
Earnings before Tax (EBT) 1 3.15 11.03 13.42 5.892 2.284 -102.6
Net income 1 0.2729 6.965 10.05 4.495 0.8821 -64.81
Net margin 0.68% 5.61% 7.1% 4.48% 0.88% -93.99%
EPS 2 0.0476 1.100 1.590 0.7122 0.1397 -10.27
Free Cash Flow - -76.4 -91.57 -175.9 -130.7 -319.3
FCF margin - -61.49% -64.75% -175.27% -130.44% -463.09%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 7/20/18 9/5/19 9/5/20 12/7/21 9/6/23 9/6/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 65.9 80.3 172 333 446 571
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 6.391 x 2.436 x 3.931 x 8.331 x 11.75 x -32.15 x
Free Cash Flow - -76.4 -91.6 -176 -131 -319
ROE (net income / shareholders' equity) - 3.51% 4.25% 1.77% 0.48% -43.3%
ROA (Net income/ Total Assets) - 4.74% 4.54% 2.91% 2.05% -3.35%
Assets 1 - 146.9 221.3 154.7 42.93 1,937
Book Value Per Share 2 29.00 35.20 37.20 37.90 39.60 27.70
Cash Flow per Share 2 0.1500 5.170 0.3100 4.200 0.3700 0.1500
Capex 1 26 24.8 73.5 222 172 287
Capex / Sales 65.16% 19.93% 51.98% 221.1% 171.5% 416.09%
Announcement Date 7/20/18 9/5/19 9/5/20 12/7/21 9/6/23 9/6/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VANTA BIOSCIENCE LIMITED Stock Vanta Bioscience Limited
+23.53% 4.77M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.26% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VANTABIO6 Stock
  4. Financials Vanta Bioscience Limited